DynPort Vaccine Company LLC, A CSC Company, 64 Thomas Johnson Drive, Frederick, MD 21702, USA.
Vaccine. 2010 Apr 19;28(18):3143-51. doi: 10.1016/j.vaccine.2010.02.056. Epub 2010 Mar 1.
V3526, a genetically modified strain of Venezuelan equine encephalitis virus (VEEV), was formalin inactivated for evaluation as a next generation vaccine candidate for VEEV. In this study, we tested formalin-inactivated V3526 (fV3526) with and without adjuvant for immunogenicity and efficacy in BALB/c mice and results were compared to the existing inactivated VEEV vaccine, C84. Mice were vaccinated intramuscularly (IM) or subcutaneously (SC) with fV3526 formulations and challenged with VEEV IAB Trinidad donkey (VEEV TrD) strain by SC or aerosol exposure. Efficacy following SC or aerosol challenge was not significantly different between the fV3526 formulations or compared to C84 despite C84 being administered in more doses and higher concentration of viral protein per dose. These data support further evaluation of fV3526 formulations as a next generation VEEV vaccine.
V3526 是委内瑞拉马脑炎病毒（VEEV）的一种基因改造株，经甲醛灭活后被评估为下一代 VEEV 候选疫苗。在这项研究中，我们测试了含有和不含有佐剂的甲醛灭活 V3526（fV3526）在 BALB/c 小鼠中的免疫原性和疗效，并将结果与现有的灭活 VEEV 疫苗 C84 进行了比较。小鼠通过肌肉内（IM）或皮下（SC）接种 fV3526 制剂，并通过 SC 或气溶胶暴露接受 VEEV IAB 特立尼达驴（VEEV TrD）株的挑战。尽管 C84 的接种剂量更多，且每剂量的病毒蛋白浓度更高，但 fV3526 制剂或与 C84 相比，SC 或气溶胶挑战后的疗效并无显著差异。这些数据支持进一步评估 fV3526 制剂作为下一代 VEEV 疫苗。
